#1
#1 out of 1
health15h ago
WHO Decision Recognizing Obesity as a Disease Treatable with GLP-1 Drugs Is “Big Deal,” says BU Endocrinologist
- WHO formally recognizes obesity as a chronic disease and endorses long-term use of GLP-1 drugs for treatment.
- The guidelines aim to reduce stigma and improve access to treatment for obesity worldwide.
- BU experts anticipate policy changes to expand equitable access and lower drug costs over time.
- Insurance coverage shifts are prompting discussions on maintaining essential obesity care.
- Long-term obesity treatment could reduce related health costs and improve productivity, BU notes.
- Obesity is framed as a chronic, relapsing disease requiring ongoing management, not a one-time fix.
- The guidance encourages accompanying behavioral therapy and lifestyle measures with pharmacotherapy.
- BU endocrinologist emphasizes treating obesity without blame, focusing on healthy outcomes.
- The WHO guidelines may accelerate global efforts to increase GLP-1 drug production and lower prices.
Vote 0